1 – 10 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
- IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951
- 2014
- Dexamethasone (6 mg/m²/day) and prednisolone (60 mg/m²/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial
- Pediatric acute megakaryoblastic leukemia without Down syndrome: a retrospective study by the international Berlin-Frankfurt-Munster study group (I-BFMSG)
- An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions
- 2013
- Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results
- 2012
- Improved risk stratification and outcome prediction in children with average risk 1 precursor-B acute lymphoblastic leukemia using a 19-microRNA signature
- Improved risk-stratification and outcome prediction in children with average risk precursor-B acute lymphoblastic leukemia using a 19-microRNA signature
- 2011
- EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells
- Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
- 2010
- NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951